Intocell Inc

287840

Company Profile

  • Business description

    Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.

  • Contact

    101 Sinildong-ro
    Daedeok-gu
    Daejeon
    KOR

    T: +82 427160083

    https://www.intocell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,979.4022.00-0.24%
CAC 407,818.2832.15-0.41%
DAX 4024,295.9355.110.23%
Dow JONES (US)44,849.59160.70-0.36%
FTSE 1009,138.3776.880.85%
HKSE25,667.18129.110.51%
NASDAQ21,077.5557.530.27%
Nikkei 22541,826.34655.021.59%
NZX 50 Index12,805.1311.070.09%
S&P 5006,375.3416.430.26%
S&P/ASX 2008,709.4027.80-0.32%
SSE Composite Index3,605.7323.430.65%

Market Movers